Provided by Tiger Fintech (Singapore) Pte. Ltd.

Incyte

59.00
-0.2250-0.38%
Volume:32.24K
Turnover:1.91M
Market Cap:11.42B
PE:393.30
High:59.27
Open:59.17
Low:58.65
Close:59.22
Loading ...

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

StockStory
·
4 hours ago

Incyte Corp. Stock Advances 4.1%, Outperforms Competitors

Dow Jones
·
17 hours ago

Incyte Corp. Stock Underperforms Friday When Compared To Competitors Despite Daily Gains

Dow Jones
·
12 Apr

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
11 Apr

Incyte Faces Limited Exposure From Tariffs on Dual Sourcing, UBS Says

MT Newswires Live
·
11 Apr

Press Release: Incyte to Report First Quarter Financial Results

Dow Jones
·
10 Apr

Sun Pharmaceutical Industries Says U.S. Court Of Appeals Vacates Preliminary Injunction On Leqselvi

Reuters
·
10 Apr

Incyte price target lowered to $61 from $69 at UBS

TIPRANKS
·
09 Apr

Incyte Corp. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
09 Apr

AbbVie's Rinvoq Gets EU Nod for 8th Indication Giant Cell Arteritis

Zacks
·
08 Apr

BRIEF-Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Apr

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
08 Apr

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire
·
08 Apr

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

StockStory
·
07 Apr

Incyte Corp. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
05 Apr

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Zacks
·
04 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
04 Apr

RBC Lowers Price Target on Incyte to $64 From $68, Keeps Sector Perform Rating

MT Newswires Live
·
03 Apr

Incyte Corp. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
03 Apr

BUZZ-Compass Therapeutics falls; brokerage says cancer drug trial data underwhelms

Reuters
·
01 Apr